Skip to content

Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial

Investigating Various Adaptive-Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment (ACTIVATE)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04667481
Acronym
ACTIVATE
Enrollment
27
Registered
2020-12-14
Start date
2022-01-05
Completion date
2022-11-10
Last updated
2024-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Invasive Breast Carcinoma

Keywords

breast cancer, exercise, fatigue, fitness, aerobic, survivor

Brief summary

This clinical trial studies the feasibility of implementing various adaptive training exercise programs to improve cardiorespiratory fitness in patients after receiving breast cancer treatment. Information from this study may help researchers better understand how to implement adaptive training interventions to improve cardiorespiratory fitness in patients after receiving breast cancer treatment.

Detailed description

OUTLINE: Patients are randomized to the interventional groups or control group. INTERVENTION GROUPS: Patients are randomized to 1 of 2 interventional arms. ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks. ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks. CONTROL GROUP: After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.

Interventions

Participate in aerobic exercise intervention

Participate in resistance exercise intervention

OTHERExercise Intervention: Digital copies and outline of sessions

Receive digital copy of AE and RE sessions and an outline of sessions

OTHERQuestionnaire Administration

Ancillary studies

OTHERQuality-of-Life Assessment

Ancillary studies

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18 - 75 years, inclusive 2. Female gender 3. Prior diagnosis of invasive breast cancer 4. Completion of chemotherapy or receipt of trastuzumab (Herceptin) therapy within the past 6 - 60 months (0.5 - 5 years) 5. Reduced cardiorespiratory functional capacity, defined as below the median estimated CRF for age/sex-matched controls

Exclusion criteria

1. Actively receiving radiation treatment 2. Medical history of heart failure, coronary artery disease or arrhythmia 3. Contraindications to cardiopulmonary exercise testing (CPET) 4. Contraindications to magnetic resonance imaging (MRI) (e.g ferromagnetic cerebral aneurysm clips or other intraorbital/intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices, non-compatible MRI tissue expanders or breast implants, or other implanted non-compatible MRI devices), weight over 550 lbs, or symptomatic claustrophobia 5. Contraindications to exercise, including a history of surgery with sequelae that restrict ability to exercise safely or comfortably 6. Unwilling to complete intervention procedures or outcome measures

Design outcomes

Primary

MeasureTime frameDescription
Intervention FeasibilityWeek 24Will be determined with all-cause intervention discontinuation rate, which is the proportion of all intervention participants who permanently stop the intervention prior to week 24 for any reason.

Secondary

MeasureTime frameDescription
Intervention Safety: Adverse EventsUp to 24 weeksIntervention safety will be determined by reviewing and quantifying the number of adverse events (mild, moderate, or severe), serious adverse events, and by reviewing the type and severity of adverse events attributed to study procedures among each study group.
Study FeasibilityUp to 24 weeksStudy feasibility will be measured by calculating recruitment rates (proportion of enrolled participants to all individuals approached), and loss to follow-up (proportion of participants who do not complete post-intervention assessments). A benchmark to determine feasibility is \< 40% loss to follow-up.
Intervention AcceptabilityUp to 24 weeksAcceptability will be measured with qualitative, open-ended to assess participant experience in the intervention and gather information for improving the protocol in future studies. Of particular attention will be the tolerability of a remote, home-based exercise intervention with a semi supervised format.
Intervention Session IntensityUp to 24 weeksThe Rating of Perceived Exertion (RPE) scale asks respondents to rate the intensity of exercise on a 1-10 scale, with higher values representing greater perceived exertion (1 = Very Light Activity, 10 = Maximum Possible Exertion). The measure has been validated for estimating both aerobic and resistance exercise exertion levels, providing a standard measure across intervention modalities. The average RPE for full-intensity sessions (the first few weeks involve an increasing RPE across sessions) will be calculated for each participant.
Intervention AdherenceUp to 24 weeksParticipants will complete an RPE rating after each session. These ratings will be used to calculate adherence rate for each participant. A session with an RPE that is at or above the intended RPE will be considered adherent. The number of adherent sessions will be divided by the total number of sessions, whether the session was attended or not. The participant adherence rates will be averaged to find a mean adherence rate per participant.

Other

MeasureTime frameDescription
Abdominal Deposits of FatUp to 24 weeksSubcutaneous (SQ) fat and visceral adipose tissue (VAT) will be assessed via abdominal MRI. For analysis, fat depots will be separated into abdominal SQ fat and VAT which will be further segmented into intraperitoneal (IP) and retroperitoneal (RP) fat using commercially available software. SQ fat will be defined as the fat outside the muscular abdominal wall; IP fat as fat within the mesentery and omentum bounded anteriorly and laterally by the abdominal wall and posteriorly by a curved line drawn between the kidneys; RP fat as the remaining fat. Adipose tissues will be segmented and colored from other tissues based on pixel intensity and known divisions of tissue planes. The MRI analyst, blinded to participant characteristics, will correct any misidentified fat or non-fat regions using manual tools provided within the software. To calculate each of the compartmental fat deposits, the number of subpixels within each fat compartment.
Intermuscular Fat (IMF)Up to 24 weeksThe ratio of thigh IMF to skeletal muscle (SM) will be ascertained via magnetic resonance imaging (MRI) by trained MRI technologists. Participants will undergo a screening process with the MRI technologist to ensure that eligibility criteria for MRI scans are met. Participants will then change into a hospital gown and enter the MRI scanner. In this longitudinal assessment of IMF, the MRI technologist will be instructed to match participant scan positions across time by matching the current scan position with the participant's previous scan position, recorded at the timepoint prior. MRI analysts will quantitate total and compartment amounts of muscle and adipose tissue using cross-sectional areas of thigh skeletal muscle (SM) and IMF using commercially available software. Thigh IMF area will be calculated as the number of fat pixels within the thigh musculature multiplied by the pixel surface area.
Anthropometrics (Waist Circumference)Up to 24 weeksWaist circumference will be measured to the nearest one-tenth cm.
Change in Quality of LifeUp to 24 weeksThe Short Form Health Survey-36 (SF-36) is a widely used self-report measure of quality of life and health status. Comprised of 36 multiple choice questions, the SF-36 queries general perceptions a participant has about their health, as well as limitations to physical activity, physical health problems, mental health problems, pain, and energy/fatigue. The SF-36 is used across health research domains, and in breast cancer has been validated as a reliable longitudinal monitor of quality of life.
Maximal Exercise Capacity (Absolute)Up to 24 weeksThis is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (absolute).
Perceived Well-beingUp to 24 weeksParticipants' perception of their current well-being will be assessed with the 28-item 5-point Likert scale Functional Assessment of Cancer Therapy (FACT)-General. The FACT-G contains 4 subscales measuring physical, social, emotional, and functional well-being and has been validated for reliably measuring well-being in cancer patients.
Physical Activity and Sedentary Behaviors (SBQ)Up to 24 weeksTime spent engaging in sedentary lifestyle behaviors will be measured with the self-administered Sedentary Behaviors Questionnaire (SBQ). The SBQ measures the minutes spent participating in 9 different sedentary behaviors per typical weekday and weekend day.
Level of FatigueUp to 24 weeksThe Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale is a 13-item scale originally developed for and widely used to assess cancer-related fatigue. The FACIT-Fatigue scale measures severity (i.e., I feel fatigued; I feel weak all over) and impact of fatigue (e.g., I need help doing my usual activities; I have to limit my social activity because I am tired) over the past week, with responses scored on a 5-point scale, from 0 not at all to 4 very much. The FACIT-Fatigue scale has excellent psychometric properties and a focus on physical aspects of fatigue.
Physical Activity and Sedentary Behaviors (IPAQ)Up to 24 weeksTime spent engaging in physical activity will be measured with the Physical Activity Recall Interview. The PAR assesses time spent in physical activity over the past 7 days.
Maximal Exercise Capacity (Relative to Bodyweight)Up to 24 weeksThis is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (relative to bodyweight).
Submaximal Exercise CapacityUp to 24 weeksSubmaximal exercise capacity, also considered functional capacity, will be determined with the six minute walk test (6MWT), which measures the distance a person can walk in six minutes (6MWD). A widely used measure of submaximal exercise capacity, the 6MWT will be administered at all study timepoints to evaluate intervention response.
Anthropometrics (Weight)Up to 24 weeksPrior to the measurement of body weight, participants will be instructed to remove heavy clothing and empty pockets of their contents. Weight will be measured to the nearest one-tenth kg with a calibrated balance beam or digital scale.
Anthropometrics (Hip Circumference)Up to 24 weeksHip circumference will be measured to the nearest one-tenth cm.
Anthropometrics (Height)Up to 24 weeksHeight will be measured while the participant stands without shoes using a wall-mounted stadiometer to the nearest one-tenth cm.

Countries

United States

Participant flow

Participants by arm

ArmCount
Arm I (Aerobic Exercise)
Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks. Aerobic Exercise Intervention: Participate in aerobic exercise intervention Resistance Exercise Intervention: Participate in resistance exercise intervention Quality-of-Life Assessment: Ancillary studies
9
Arm II (Resistance Exercise)
Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks. Aerobic Exercise Intervention: Participate in aerobic exercise intervention Resistance Exercise Intervention: Participate in resistance exercise intervention Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
9
Control Group (Digital Exercise Interventions)
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
9
Total27

Baseline characteristics

CharacteristicArm I (Aerobic Exercise)Arm II (Resistance Exercise)Control Group (Digital Exercise Interventions)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants0 Participants3 Participants4 Participants
Age, Categorical
Between 18 and 65 years
8 Participants9 Participants6 Participants23 Participants
Age, Continuous58.9 years
STANDARD_DEVIATION 5.7
48.9 years
STANDARD_DEVIATION 11.7
56.6 years
STANDARD_DEVIATION 11.6
54.8 years
STANDARD_DEVIATION 10.6
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants9 Participants9 Participants27 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
1 Participants3 Participants0 Participants4 Participants
Race (NIH/OMB)
Black or African American
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
6 Participants6 Participants8 Participants20 Participants
Sex: Female, Male
Female
9 Participants9 Participants9 Participants27 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 90 / 90 / 9
other
Total, other adverse events
9 / 99 / 99 / 9
serious
Total, serious adverse events
0 / 90 / 90 / 9

Outcome results

Primary

Intervention Feasibility

Will be determined with all-cause intervention discontinuation rate, which is the proportion of all intervention participants who permanently stop the intervention prior to week 24 for any reason.

Time frame: Week 24

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Arm I: Aerobic ExerciseIntervention FeasibilityDiscontinued Intervention1 Participants
Arm I: Aerobic ExerciseIntervention FeasibilityCompleted Intervention8 Participants
Arm II: Resistance ExerciseIntervention FeasibilityDiscontinued Intervention3 Participants
Arm II: Resistance ExerciseIntervention FeasibilityCompleted Intervention6 Participants
Secondary

Intervention Acceptability

Acceptability will be measured with qualitative, open-ended to assess participant experience in the intervention and gather information for improving the protocol in future studies. Of particular attention will be the tolerability of a remote, home-based exercise intervention with a semi supervised format.

Time frame: Up to 24 weeks

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Arm I: Aerobic ExerciseIntervention AcceptabilitySatisfied with sessions9 Participants
Arm I: Aerobic ExerciseIntervention AcceptabilityExercise Provided Enough Challenge9 Participants
Arm I: Aerobic ExerciseIntervention AcceptabilityDesired more personalized instruction3 Participants
Arm II: Resistance ExerciseIntervention AcceptabilitySatisfied with sessions9 Participants
Arm II: Resistance ExerciseIntervention AcceptabilityExercise Provided Enough Challenge9 Participants
Arm II: Resistance ExerciseIntervention AcceptabilityDesired more personalized instruction4 Participants
Secondary

Intervention Adherence

Participants will complete an RPE rating after each session. These ratings will be used to calculate adherence rate for each participant. A session with an RPE that is at or above the intended RPE will be considered adherent. The number of adherent sessions will be divided by the total number of sessions, whether the session was attended or not. The participant adherence rates will be averaged to find a mean adherence rate per participant.

Time frame: Up to 24 weeks

ArmMeasureValue (MEAN)Dispersion
Arm I: Aerobic ExerciseIntervention Adherence52.8 percentage of adherent sessionsStandard Deviation 31
Arm II: Resistance ExerciseIntervention Adherence40.7 percentage of adherent sessionsStandard Deviation 32.2
Secondary

Intervention Safety: Adverse Events

Intervention safety will be determined by reviewing and quantifying the number of adverse events (mild, moderate, or severe), serious adverse events, and by reviewing the type and severity of adverse events attributed to study procedures among each study group.

Time frame: Up to 24 weeks

Population: Only adverse events probably or definitely attributed to study procedures are counted.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsCount of participants with at least one AE2 Participants
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsGastrointestinal/Digestive0 Participants
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsRespiratory0 Participants
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsSkin0 Participants
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsMusculoskeletal2 Participants
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsNervous System/Neurological0 Participants
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsPsychiatric0 Participants
Arm I: Aerobic ExerciseIntervention Safety: Adverse EventsInjuries1 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsRespiratory1 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsPsychiatric0 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsSkin0 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsMusculoskeletal3 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsNervous System/Neurological0 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsCount of participants with at least one AE3 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsGastrointestinal/Digestive0 Participants
Arm II: Resistance ExerciseIntervention Safety: Adverse EventsInjuries2 Participants
Control GroupIntervention Safety: Adverse EventsRespiratory0 Participants
Control GroupIntervention Safety: Adverse EventsGastrointestinal/Digestive0 Participants
Control GroupIntervention Safety: Adverse EventsCount of participants with at least one AE0 Participants
Control GroupIntervention Safety: Adverse EventsSkin0 Participants
Control GroupIntervention Safety: Adverse EventsPsychiatric0 Participants
Control GroupIntervention Safety: Adverse EventsNervous System/Neurological0 Participants
Control GroupIntervention Safety: Adverse EventsMusculoskeletal0 Participants
Control GroupIntervention Safety: Adverse EventsInjuries0 Participants
Secondary

Intervention Session Intensity

The Rating of Perceived Exertion (RPE) scale asks respondents to rate the intensity of exercise on a 1-10 scale, with higher values representing greater perceived exertion (1 = Very Light Activity, 10 = Maximum Possible Exertion). The measure has been validated for estimating both aerobic and resistance exercise exertion levels, providing a standard measure across intervention modalities. The average RPE for full-intensity sessions (the first few weeks involve an increasing RPE across sessions) will be calculated for each participant.

Time frame: Up to 24 weeks

ArmMeasureValue (MEAN)Dispersion
Arm I: Aerobic ExerciseIntervention Session Intensity5.86 units on a scaleStandard Deviation 1.37
Arm II: Resistance ExerciseIntervention Session Intensity5.60 units on a scaleStandard Deviation 1.62
Secondary

Study Feasibility

Study feasibility will be measured by calculating recruitment rates (proportion of enrolled participants to all individuals approached), and loss to follow-up (proportion of participants who do not complete post-intervention assessments). A benchmark to determine feasibility is \< 40% loss to follow-up.

Time frame: Up to 24 weeks

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Arm I: Aerobic ExerciseStudy FeasibilityDid not complete endpoint assessment2 Participants
Arm I: Aerobic ExerciseStudy FeasibilityCompleted endpoint assessment25 Participants
Other Pre-specified

Abdominal Deposits of Fat

Subcutaneous (SQ) fat and visceral adipose tissue (VAT) will be assessed via abdominal MRI. For analysis, fat depots will be separated into abdominal SQ fat and VAT which will be further segmented into intraperitoneal (IP) and retroperitoneal (RP) fat using commercially available software. SQ fat will be defined as the fat outside the muscular abdominal wall; IP fat as fat within the mesentery and omentum bounded anteriorly and laterally by the abdominal wall and posteriorly by a curved line drawn between the kidneys; RP fat as the remaining fat. Adipose tissues will be segmented and colored from other tissues based on pixel intensity and known divisions of tissue planes. The MRI analyst, blinded to participant characteristics, will correct any misidentified fat or non-fat regions using manual tools provided within the software. To calculate each of the compartmental fat deposits, the number of subpixels within each fat compartment.

Time frame: Up to 24 weeks

Other Pre-specified

Anthropometrics (Height)

Height will be measured while the participant stands without shoes using a wall-mounted stadiometer to the nearest one-tenth cm.

Time frame: Up to 24 weeks

Other Pre-specified

Anthropometrics (Hip Circumference)

Hip circumference will be measured to the nearest one-tenth cm.

Time frame: Up to 24 weeks

Other Pre-specified

Anthropometrics (Waist Circumference)

Waist circumference will be measured to the nearest one-tenth cm.

Time frame: Up to 24 weeks

Other Pre-specified

Anthropometrics (Weight)

Prior to the measurement of body weight, participants will be instructed to remove heavy clothing and empty pockets of their contents. Weight will be measured to the nearest one-tenth kg with a calibrated balance beam or digital scale.

Time frame: Up to 24 weeks

Other Pre-specified

Change in Quality of Life

The Short Form Health Survey-36 (SF-36) is a widely used self-report measure of quality of life and health status. Comprised of 36 multiple choice questions, the SF-36 queries general perceptions a participant has about their health, as well as limitations to physical activity, physical health problems, mental health problems, pain, and energy/fatigue. The SF-36 is used across health research domains, and in breast cancer has been validated as a reliable longitudinal monitor of quality of life.

Time frame: Up to 24 weeks

Other Pre-specified

Intermuscular Fat (IMF)

The ratio of thigh IMF to skeletal muscle (SM) will be ascertained via magnetic resonance imaging (MRI) by trained MRI technologists. Participants will undergo a screening process with the MRI technologist to ensure that eligibility criteria for MRI scans are met. Participants will then change into a hospital gown and enter the MRI scanner. In this longitudinal assessment of IMF, the MRI technologist will be instructed to match participant scan positions across time by matching the current scan position with the participant's previous scan position, recorded at the timepoint prior. MRI analysts will quantitate total and compartment amounts of muscle and adipose tissue using cross-sectional areas of thigh skeletal muscle (SM) and IMF using commercially available software. Thigh IMF area will be calculated as the number of fat pixels within the thigh musculature multiplied by the pixel surface area.

Time frame: Up to 24 weeks

Other Pre-specified

Level of Fatigue

The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale is a 13-item scale originally developed for and widely used to assess cancer-related fatigue. The FACIT-Fatigue scale measures severity (i.e., I feel fatigued; I feel weak all over) and impact of fatigue (e.g., I need help doing my usual activities; I have to limit my social activity because I am tired) over the past week, with responses scored on a 5-point scale, from 0 not at all to 4 very much. The FACIT-Fatigue scale has excellent psychometric properties and a focus on physical aspects of fatigue.

Time frame: Up to 24 weeks

Other Pre-specified

Maximal Exercise Capacity (Absolute)

This is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (absolute).

Time frame: Up to 24 weeks

Other Pre-specified

Maximal Exercise Capacity (Relative to Bodyweight)

This is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (relative to bodyweight).

Time frame: Up to 24 weeks

Other Pre-specified

Perceived Well-being

Participants' perception of their current well-being will be assessed with the 28-item 5-point Likert scale Functional Assessment of Cancer Therapy (FACT)-General. The FACT-G contains 4 subscales measuring physical, social, emotional, and functional well-being and has been validated for reliably measuring well-being in cancer patients.

Time frame: Up to 24 weeks

Other Pre-specified

Physical Activity and Sedentary Behaviors (IPAQ)

Time spent engaging in physical activity will be measured with the Physical Activity Recall Interview. The PAR assesses time spent in physical activity over the past 7 days.

Time frame: Up to 24 weeks

Other Pre-specified

Physical Activity and Sedentary Behaviors (SBQ)

Time spent engaging in sedentary lifestyle behaviors will be measured with the self-administered Sedentary Behaviors Questionnaire (SBQ). The SBQ measures the minutes spent participating in 9 different sedentary behaviors per typical weekday and weekend day.

Time frame: Up to 24 weeks

Other Pre-specified

Submaximal Exercise Capacity

Submaximal exercise capacity, also considered functional capacity, will be determined with the six minute walk test (6MWT), which measures the distance a person can walk in six minutes (6MWD). A widely used measure of submaximal exercise capacity, the 6MWT will be administered at all study timepoints to evaluate intervention response.

Time frame: Up to 24 weeks

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026